BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/14/2018 2:12:17 AM | Browse: 1389 | Download: 2699
 |
Received |
|
2018-03-27 00:51 |
|
Peer-Review Started |
|
2018-03-27 06:51 |
|
First Decision by Editorial Office Director |
|
2018-04-23 01:49 |
|
Return for Revision |
|
2018-04-24 06:04 |
|
Revised |
|
2018-07-03 18:10 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-07-06 09:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-07-10 23:06 |
|
Articles in Press |
|
2018-07-10 23:06 |
|
Edit the Manuscript by Language Editor |
|
2018-07-23 15:45 |
|
Typeset the Manuscript |
|
2018-09-13 01:55 |
|
Publish the Manuscript Online |
|
2018-09-14 02:12 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Basic Study |
| Article Title |
Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vladislav A Zykov, Taisiia P Tuchina, Denis A Lebedev, Irina B Krylova, Alina Y Babenko, Elvira V Kuleshova, Elena N Grineva, Alekber A Bayramov and Michael M Galagudza |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Russian Science Foundation |
17-75-30052 |
|
| Corresponding Author |
Alina Y Babenko, DSc, MD, PhD, Doctor, Doctor, Research Scientist, Institute of Endocrinology, Almazov National Medical Research Centre, Akkuratova St., 2, St-Petersburg 197341, Russia. babenko@almazovcentre.ru |
| Key Words |
Glucagon-like peptide-1 analog; Insulin; Myocardial ischemia-reperfusion injury; Infarct size; Type 2 diabetes mellitus; Rats; Experimental research |
| Core Tip |
In addition to their glucose-lowering effects, glucagon-like peptide-1 analogs (GLP-1a) were shown to exhibit cardioprotective effects. However, the optimal protocol of GLP-1a administration for infarct size reduction has not been determined yet. Additionally, it is important to investigate the effects of GLP-1a combined with other antidiabetic drugs on myocardial infarct size. Thus, we evaluated the effects of GLP-1a with and without insulin on infarct size in rats with type 2 diabetes mellitus. We found that GLP-1a administration prior to ischemia resulted in significant infarct size reduction. Infarct size reduction was maximal in rats treated with GLP-1a before ischemia plus insulin at reperfusion. |
| Publish Date |
2018-09-14 02:12 |
| Citation |
Zykov VA, Tuchina TP, Lebedev DA, Krylova IB, Babenko AY, Kuleshova EV, Grineva EN, Bayramov AA, Galagudza MM. Effects of glucagon-like peptide 1 analogs in combination with insulin on myocardial infarct size in rats with type 2 diabetes mellitus. World J Diabetes 2018; 9(9): 149-156 |
| URL |
http://www.wjgnet.com/1948-9358/full/v9/i9/149.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v9.i9.149 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
